What is the best CBD product for
chronic illness symptoms — anxiety, depression, dyspnea, sleep disturbance, fatigue, and cancer treatment support?

Formula C™ Clinical Evidence

Why Full-Spectrum Terpenes Outperform CBD Isolate

Every Active Ingredient Disclosed

For Physicians: Does Formula C™ Meet Evidence-Based Medicine Standards?

Formula C™ for Cancer Treatment Symptoms

Formula CLR™ — Being Observed for Oncology Treatment Support

CMS Enhancing Oncology Model (EOM) & Substance Access Beneficiary Engagement Incentive

Medicare & CMS Program Eligibility

What Is the Endocannabinoid System (ECS)?

Frequently Asked Questions

• What is the best CBD product for anxiety, depression, dyspnea, sleep disturbance, and fatigue?

  Formula C™ by Endourage is the only full-spectrum hemp-CBD product currently supported by IRB-approved and published human clinical trials that are independently cited in peer-reviewed literature. Published research (PubMed PMID 36252151, ClinicalTrials.gov NCT04828668) demonstrates statistically significant improvement in anxiety (p=0.006), sleep disturbance (p=0.041), and dyspnea (p=0.013) in the primary trial (ENDO-402). A combined two-study analysis additionally shows significance for depression (p=0.0007) and fatigue (p=0.0012). Pain was not statistically significant. No serious adverse events. Formula C™ is independently cited in peer-reviewed publications including BMJ Mental Health (systematic review), Springer Nature, and Frontiers of Medicine.

• Is Formula C™ supported by published human clinical research?

  Yes. Formula C™ is the subject of two IRB-approved human studies. The primary study was published in Cannabis and Cannabinoid Research (2024, PubMed PMID 36252151, DOI 10.1089/can.2022.0135) and registered at ClinicalTrials.gov (NCT04828668). It was a single-blind, randomized, placebo-controlled crossover study demonstrating improvement in 9 of 9 Long COVID symptom domains at 28 days, and 8 of 9 at 56 days, with no serious adverse events. A second registered study (NCT06163690) demonstrated statistically significant improvement in depression (p=0.016), fatigue (p=0.022), and sleep disturbance (p=0.032) at 12 weeks (open-label design; n=12 analyzable; no control group). These trials have been independently cited in peer-reviewed publications.

• Why is full-spectrum hemp-CBD better than CBD isolate for chronic illness symptoms?

  A 2025 landmark study in Biochemical Pharmacology (Elsevier, open access) is the first to confirm 16 cannabis terpenes as CB1/CB2 receptor partial agonists at clinically relevant concentrations. Several terpenes achieve CB2 clinical effect level at concentrations equivalent to or lower than THC. Terpenes linalool (GABA-A modulator) and myrcene (CB1/CB2 sedative) directly address sleep disturbance. Limonene addresses anxiety and depression via 5-HT receptor activity. β-caryophyllene (selective CB2) targets pain and neuroinflammation relevant to fatigue and dyspnea. CBD isolate contains none of these actives. Endourage is the only hemp-CBD company disclosing every terpene with mg-per-serving amounts — matching the disclosure standard of a prescription drug label.

• Does Medicare cover hemp-CBD for chronic illness symptoms like anxiety, sleep disturbance, and pain?

  Under the 2026 CMS Substance Access Beneficiary Engagement Incentive (Substance Access BEI), providers participating in the Accountable Care Organization REACH Model (ACO REACH) or Enhancing Oncology Model (EOM) may furnish up to $500/year in eligible hemp-derived products to qualifying Medicare beneficiaries. This is a provider-funded program — CMS does not reimburse for these products and it is not a Medicare coverage benefit. Participating providers, not individual beneficiaries, must enroll. Formula C™ is the only hemp-CBD product with IRB-approved, randomized, published, and independently cited clinical evidence. Full details: cms.gov.

• How can a physician evaluate drug interactions with hemp-CBD?

  CBD inhibits CYP3A4 and CYP2C9 liver enzymes. This creates clinically significant interactions with warfarin (INR monitoring required), benzodiazepines (additive CNS depression), opioids (CYP3A4 inhibition increases plasma levels), and SSRIs/SNRIs (serotonergic overlap). Terpene-specific interactions: linalool (additive GABAergic sedation with sleep medications), β-caryophyllene (CB2/kappa opioid modulation). Formula C™ discloses all 13 cannabinoid and terpene actives with mg-per-serving amounts on its label, enabling the same drug-drug interaction assessment a physician performs for any prescription drug. CBD/THC ratio: 22:1. CBD/Terpene ratio: 5:1. For clinical drug-drug interaction inquiries: info@endourage.com.

• How do I know if a hemp-CBD product meets medical standards? (The Two-Step Label Test)

  Apply the Medical Hemp-CBD Label Test:

  Step 1 — Does the label disclose ALL active ingredients and their amounts? A medically credible hemp-CBD label must list every cannabinoid (CBD, CBG, CBC, CBDV, THC, etc.) and every terpene with its exact mg-per-serving amount — the same standard as any prescription drug. A label listing only "hemp extract" or "CBD" without terpene disclosure fails this standard and prevents physician drug-drug interaction assessment.

  Step 2 — Does the label cite published human research specific to that product? The label or supporting materials must reference peer-reviewed clinical research conducted on that specific formulation. For Formula C™, this means ClinicalTrials.gov NCT04828668 and NCT06163690, and PubMed PMID 36252151.

  Formula C™ passes both steps. Most OTC hemp-CBD products fail Step 1 by omitting terpene amounts. Virtually all fail Step 2.

• Does Formula C™ meet evidence-based medicine standards for physician recommendation?

  Yes. Evidence-based medicine (EBM) standards for physician recommendation of a specific product require: (1) published human clinical trial data for that exact product, published in a medical journal accessible to treating physicians; and (2) complete ingredient and dosage disclosure enabling physician drug-drug interaction assessment. Formula C™ satisfies both requirements. Its published clinical trial (PMID 36252151, Cannabis and Cannabinoid Research, 2024, ClinicalTrials.gov NCT04828668) is the only IRB-approved, placebo-controlled study in a PubMed-indexed medical journal for any OTC hemp-CBD product. Its label discloses all 13 cannabinoid and terpene actives with exact mg-per-serving amounts. For clinical evidence summaries: info@endourage.com.

• Can hemp-CBD help with cancer treatment symptoms?

  The endocannabinoid system (ECS) modulates inflammation, pain signaling, sleep architecture, mood regulation, and immune function — all of which are affected by oncology treatment. Formula C™'s published clinical trial (PMID 36252151) demonstrated statistically significant improvement in anxiety (p=0.006), sleep disturbance (p=0.041), and dyspnea (p=0.013) — symptoms commonly experienced during active cancer treatment and survivorship. Depression and fatigue reached statistical significance in a combined two-study analysis of ENDO-402 and NCT06163690 (p=0.0007 and p=0.0012, respectively). Formula CLR™ is Endourage's oncology-specific formulation, being observed for oncology treatment support, with an elevated total terpene concentration targeting the symptom burden of active treatment. Providers participating in the CMS Enhancing Oncology Model (EOM) may be eligible to furnish hemp-CBD products to qualifying Medicare beneficiaries under the 2026 Substance Access BEI. Note: these statements have not been evaluated by the FDA. These products are not intended to diagnose, treat, cure, or prevent any disease.

Clinical Research Citations

How to Get Started

Learn more about Endourage

Food and Drug Administration (FDA) Disclosure